Stock Analysis
Nektar Therapeutics (NKTR) Stock Analysis
Nektar Therapeutics (NKTR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Nektar Therapeutics (NKTR) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 49/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NKTR at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $37.27 |
| AIQ Score | 39/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.27B |
| P/E Ratio (TTM) | -5.77 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.63 |
| Revenue (Q3 FY2026) | $9.39M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1 |
| Volume | 695.17K |
| 52-week range | $33.40-$109.00 |
| RSI 14 | 37.87 |
| 50-Day SMA | $48.47 |
| 200-Day SMA | $65.05 |
| Analyst Price Target | $95.75 |
| Next Earnings | Mar 2, 2027 |
NKTRNektar Therapeutics
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum25
- Value47
- Quality49
- Risk resilience41
- Sentiment—
NKTR Stock Analysis Summary
Nektar Therapeutics (NKTR) currently has an AIQ Score of 39/100, indicating a bearish setup. Quality is the strongest factor at 49/100. Momentum is the weakest current factor at 25/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, NKTR has AIQ Score of 39/100 with Quality base of 49/100 and fading Momentum at 25/100. Wait for component alignment before adding exposure.
Quality (49/100) leads while Momentum (25/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.05% stock move · NKTR classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NKTR Bullish or Bearish Right Now?
NKTR currently has a bearish overall setup. Quality is the strongest factor at 49/100, while Momentum is weakest at 25/100. The current evidence suggests a bearish setup.
- - Analyst target implies +156.91% upside from the latest quote.
- - Value is the current constraint at 47/100.
- - Momentum is weak at 25/100.
- - Risk Resilience is weak at 41/100.
- - Price is -42.71% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (34 vs 3).
Current Consensus
NKTR's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 9 neutral, and 34 sell votes. NKTR's 14-day RSI is 37.87, which places the stock in a weaker momentum range. NKTR's beta is 1, indicating market sensitivity broadly in line with the market.
What Changed in NKTR?
The largest recent change in NKTR is Quality moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the NKTR Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NKTR Decision Framework
Public evidence layers, setup checks, and risk context for Nektar Therapeutics.
Nektar Therapeutics (NKTR) Stock Analysis
Nektar Therapeutics has an AIQ Score of 39/100 in a Bearish regime. Quality is strongest at 49/100. Beta is 1, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NKTR is in a Bearish AIQ regime with score 39/100. |
| Signal Conflict | The primary conflict is that quality leads at 49/100 while momentum lags at 25/100. |
| Factor Evidence | Momentum 25/100 · Value 47/100 · Quality 49/100 · Risk 41/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 49/100.
Momentum is 25/100 and RSI (14) is 37.9.
NKTR is in a Bearish regime at 39/100.
Risk factor is 41/100 with beta 1 and annual volatility 84.03%.
Current conflict: quality leads at 49/100 while momentum lags at 25/100.
NKTR Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NKTR Fundamentals
NKTR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NKTR Technical Analysis
NKTR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NKTR Stock Catalysts
Track NKTR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NKTR Dividend Analysis
NKTR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NKTR Financial Data
NKTR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NKTR Risk Analysis
NKTR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NKTR Stock News
NKTR stock news, market tone, recent headlines, and catalyst context.
NKTR vs Biotechnology Peers
Current peer cohort: NKTR · NRIX · NVAX · OCUL · OMER. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NKTR Current stock | 39/100 | 47/100 | 25/100 | 41/100 | -0.11 | 84.03% | Current |
| NRIX Nurix Therapeutics, Inc. | 65/100 | 94/100 | 50/100 | 40/100 | 0.64 | 67.30% | NKTR vs NRIX |
| NVAX Novavax, Inc. | — | — | 77/100 | 38/100 | 0.56 | 73.62% | NKTR vs NVAX |
| OCUL Ocular Therapeutix, Inc. | 38/100 | 41/100 | 34/100 | 36/100 | -0.45 | 76.10% | NKTR vs OCUL |
| OMER Omeros Corporation | 64/100 | 73/100 | 79/100 | 33/100 | 1.36 | 110.84% | NKTR vs OMER |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NKTR: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NKTR
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NKTR
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NKTR Stock FAQ
What is NKTR stock price today?
Nektar Therapeutics's current stock price is $37.27. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NKTR bullish or bearish right now?
NKTR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NKTR's market cap?
NKTR's market cap is $1.27B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NKTR's current P/E ratio?
NKTR's current P/E ratio is -5.77 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NKTR's RSI?
NKTR's 14-day RSI is 37.87 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NKTR above its 50-day and 200-day moving averages?
NKTR is -23.11% from its 50-day SMA and -42.71% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NKTR's next earnings date?
NKTR's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NKTR pay a dividend?
NKTR's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.